Golden
Acorda Therapeutics

Acorda Therapeutics

Acorda is a biotechnology company founded in 1995 by Ron Cohen and headquartered in Ardsley, New York developing and commercializing neurology therapies for Parkinson's disease, migraines, and multiple sclerosis.

Acroda Therapeutics is a biotechnology company based out of Ardsley, New York that was founded in 1995 by Ron Cohen. The company is working to develop and commercialize treatments for neurological disorders of the central nervous system such as multiple sclerosis, spinal cord injuries, and Parkinson's disease.

Acquisitions

Biotie Therapies

On January 19, 2016 Acorda Therapeutics acquired Biotie Therapies for $25.60 per share for a total of approximately $363 million. Acorda Therapeutics bought Biotie Therapies to acquire two of its drug candidates for the treatment of Parkinson's disease called Tozadenant and SYN120. 

Timeline

People

Name
Role
LinkedIn

Abhijit Kamerkar

Employee



Akshat K Goyal

Employee



Anders Boman

Employee



Andrew Blight

Chief Scientific Officer



Andrew Hindman

Chief Business Officer



Burkhard Blank

Chief Medical Officer



Catherine Carlstedt

Employee



Christian Richardson

Employee



Christian Sabella

Employee



Daniel Aleshinloye

Employee



David Lawrence

Chief Business Operations and Principal accounting Officer



Denise Duca

Executive Vice President



Derk de Groot

Employee



Eric Chojnicki, Ph.D., M.B.A., PMP, CSSBB

Employee



Grant Levy

Employee



jane Wasman

President of International & General Counsel



Jon Mason

Employee



Kyle Kuhn

Employee



Lauren Sabella

Chief Commercial Officer



Mary Lou Nadeau

Employee



Ned McDonnell

Employee



Oksana Hradyska

Employee



Ron Cohen

Founder, President & CEO



Sissi Hai

Employee



Susan Veres

Employee



Further reading

Title
Author
Link
Type
Date

Acorda Therapeutics investor calls for company to explore sale

Greg Roumeliotis

News



Acorda Therapeutics stock rises on closure of FDA inspections

Uttara Choudhury

Web



What's Behind Acorda Therapeutics Crashing 24.5% Today -- The Motley Fool

Todd Campbell

News



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References